At the request of IIROC
Jul. 18, 2011 (Marketwire Canada) --
VANCOUVER, BRITISH COLUMBIA -- Verisante Technology, Inc. (TSX VENTURE:VRS)(OTCQX:VRSEF)(PINK SHEETS:VRSEF) (the "Company" or "Verisante"), a leader in cancer imaging technology, wishes to confirm that is it unaware of any material change in the Company's operations that would account for the recent increase in market activity.
About Veris a nte Technology, Inc.
Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined on approximately 1,000 lesions at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. The Aura and Core have not yet been approved for sale. The Company anticipates Health Canada approval for the Aura in late 2011.
Forward Looking Statements
This news release may contain assumptions, estimates, and other forward-looking statements regarding future events. Such forward-looking statements involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control that may cause actual results or performance to differ materially from those currently anticipated in such statements.
Neither The TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Verisante Technology, Inc.
President & CEO